{
	"@context": {
		"rdf": "http://www.w3.org/1999/02/22-rdf-syntax-ns#",
		"dct": "http://purl.org/dc/terms/",
		"owl": "http://www.w3.org/2002/07/owl#",
		"xsd": "http://www.w3.org/2001/XMLSchema#",
		"rdfs": "http://www.w3.org/2000/01/rdf-schema#",
		"@vocab": "http://ld.nice.org.uk/ns/bnf#",
		"bnf": "http://ld.nice.org.uk/ns/bnf/",
		"nicebnf": "http://ld.nice.org.uk/ns/bnf#",
		"route": "http://ld.nice.org.uk/ns/bnf/Route#",
		"patientGroup": "http://ld.nice.org.uk/ns/bnf/PatientGroup#",
		"indication": "http://ld.nice.org.uk/ns/bnf/Indication#",
		"sideEffect": "http://ld.nice.org.uk/ns/bnf/SideEffect#",
		"classification": "http://ld.nice.org.uk/ns/bnf/Classification#",
		"isLinkedFrom": {
			"@container": "@set"
		},
		"hasInteraction": {
			"@container": "@set"
		},
		"hasMessage": {
			"@container": "@set"
		},
		"hasInteractionList": {
			"@container": "@set"
		},
		"isInteractionListOf": {
			"@container": "@set"
		}
	},
	"@graph": [
		{
			"@id": "http://bnf.nice.org.uk/interaction/fexofenadine",
			"@type": "InteractionList",
			"hasInteraction": [
				{
					"@id": "http://bnf.nice.org.uk/interaction/fexofenadine#bnf_i1643857964182",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fexofenadine#bnf_i1643857964182_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Mild\" outputclass=\"int-message\">\n  <ph outputclass=\"int-route\">Oral</ph> <ph otherprops=\"antacids\" outputclass=\"int-drug\">antacids</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the absorption of</ph> <ph outputclass=\"int-route\">oral</ph> <ph otherprops=\"fexofenadine\" outputclass=\"int-heading-drug\">fexofenadine</ph>. <ph outputclass=\"int-action\">Manufacturer advises separate administration by 2 hours</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Mild",
							"hasOrder": "1",
							"hasTextContent": "Oral   antacids   decrease   the absorption of   oral   fexofenadine .  Manufacturer advises separate administration by 2 hours .    \n\n"
						}
					],
					"hasOrder": "1",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Antacids</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fexofenadine#bnf_i1643857964183",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fexofenadine#bnf_i1643857964183_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Mild\" outputclass=\"int-message\">\n  <ph otherprops=\"apalutamide\" outputclass=\"int-drug\">Apalutamide</ph> <ph outputclass=\"int-magnitude\">slightly</ph> <ph outputclass=\"int-effect\">decreases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"fexofenadine\" outputclass=\"int-heading-drug\">fexofenadine</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Mild",
							"hasOrder": "1",
							"hasTextContent": "Apalutamide   slightly   decreases   the exposure to   fexofenadine .  Manufacturer advises monitor .    \n\n"
						}
					],
					"hasOrder": "2",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Apalutamide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fexofenadine#bnf_i1643857964184",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fexofenadine#bnf_i1643857964184_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"berotralstat\" outputclass=\"int-drug\">Berotralstat</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"fexofenadine\" outputclass=\"int-heading-drug\">fexofenadine</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Berotralstat   is predicted to   increase   the concentration of   fexofenadine .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "3",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Berotralstat</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fexofenadine#bnf_i1643857964185",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fexofenadine#bnf_i1643857964185_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"fexofenadine\" outputclass=\"int-heading-drug\">Fexofenadine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the effects of</ph> <ph otherprops=\"betahistine\" outputclass=\"int-drug\">betahistine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Fexofenadine   is predicted to   decrease   the effects of   betahistine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "4",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Betahistine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fexofenadine#bnf_i1643857964186",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fexofenadine#bnf_i1643857964186_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"cabazitaxel\" outputclass=\"int-drug\">Cabazitaxel</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">affect</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"fexofenadine\" outputclass=\"int-heading-drug\">fexofenadine</ph>. <ph outputclass=\"int-action\">Manufacturer advises take 12 hours before or 3 hours after <ph otherprops=\"cabazitaxel\" outputclass=\"int-drug\"><xref format=\"dita\" href=\"drug/cabazitaxel.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP5557\">cabazitaxel</xref></ph></ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Cabazitaxel   is predicted to   affect   the exposure to   fexofenadine .  Manufacturer advises take 12 hours before or 3 hours after  cabazitaxel .    \n\n"
						}
					],
					"hasOrder": "5",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cabazitaxel</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fexofenadine#bnf_i1643857964187",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fexofenadine#bnf_i1643857964187_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"ceritinib\" outputclass=\"int-drug\">Ceritinib</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"fexofenadine\" outputclass=\"int-heading-drug\">fexofenadine</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution and monitor adverse effects</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Ceritinib   is predicted to   increase   the exposure to   fexofenadine .  Manufacturer advises caution and monitor adverse effects .    \n\n"
						}
					],
					"hasOrder": "6",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ceritinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fexofenadine#bnf_i1643857964188",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fexofenadine#bnf_i1643857964188_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"darolutamide\" outputclass=\"int-drug\">Darolutamide</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"fexofenadine\" outputclass=\"int-heading-drug\">fexofenadine</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Darolutamide   is predicted to   increase   the concentration of   fexofenadine .  Manufacturer advises monitor .    \n\n"
						}
					],
					"hasOrder": "7",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Darolutamide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fexofenadine#bnf_i1643857964189",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fexofenadine#bnf_i1643857964189_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"fexofenadine\" outputclass=\"int-heading-drug\">fexofenadine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   is predicted to   increase   the exposure to   fexofenadine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "8",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dronedarone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fexofenadine#bnf_i1643857964190",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fexofenadine#bnf_i1643857964190_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"elexacaftor\" outputclass=\"int-drug\">Elexacaftor</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"fexofenadine\" outputclass=\"int-heading-drug\">fexofenadine</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Elexacaftor   is predicted to   increase   the exposure to   fexofenadine .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "9",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Elexacaftor</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fexofenadine#bnf_i1643857964191",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fexofenadine#bnf_i1643857964191_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"eliglustat\" outputclass=\"int-drug\">Eliglustat</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"fexofenadine\" outputclass=\"int-heading-drug\">fexofenadine</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Eliglustat   is predicted to   increase   the exposure to   fexofenadine .  Manufacturer advises adjust dose .    \n\n"
						}
					],
					"hasOrder": "10",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Eliglustat</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fexofenadine#bnf_i1643857964192",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fexofenadine#bnf_i1643857964192_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"filgotinib\" outputclass=\"int-drug\">Filgotinib</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"fexofenadine\" outputclass=\"int-heading-drug\">fexofenadine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Filgotinib   is predicted to   increase   the exposure to   fexofenadine .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "11",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Filgotinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fexofenadine#bnf_i1643857964193",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fexofenadine#bnf_i1643857964193_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"ibrutinib\" outputclass=\"int-drug\">Ibrutinib</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"fexofenadine\" outputclass=\"int-heading-drug\">fexofenadine</ph>. <ph outputclass=\"int-action\">Manufacturer advises separate administration by at least 6 hours</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Ibrutinib   is predicted to   increase   the exposure to   fexofenadine .  Manufacturer advises separate administration by at least 6 hours .    \n\n"
						}
					],
					"hasOrder": "12",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ibrutinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fexofenadine#bnf_i1643857964194",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fexofenadine#bnf_i1643857964194_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"isocarboxazid\" outputclass=\"int-drug\">Isocarboxazid</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of antimuscarinic adverse effects when given with</ph> <ph otherprops=\"fexofenadine\" outputclass=\"int-heading-drug\">fexofenadine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Isocarboxazid   is predicted to   increase   the risk of antimuscarinic adverse effects when given with   fexofenadine .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "13",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Isocarboxazid</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fexofenadine#bnf_i1643857964195",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fexofenadine#bnf_i1643857964195_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"ivacaftor\" outputclass=\"int-drug\">Ivacaftor</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"fexofenadine\" outputclass=\"int-heading-drug\">fexofenadine</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Ivacaftor   is predicted to   increase   the exposure to   fexofenadine .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "14",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ivacaftor</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fexofenadine#bnf_i1643857964196",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fexofenadine#bnf_i1643857964196_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"lapatinib\" outputclass=\"int-drug\">Lapatinib</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"fexofenadine\" outputclass=\"int-heading-drug\">fexofenadine</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Lapatinib   is predicted to   increase   the exposure to   fexofenadine .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "15",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lapatinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fexofenadine#bnf_i1643857964197",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fexofenadine#bnf_i1643857964197_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"leflunomide\" outputclass=\"int-drug\">Leflunomide</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"fexofenadine\" outputclass=\"int-heading-drug\">fexofenadine</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Leflunomide   is predicted to   increase   the exposure to   fexofenadine .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "16",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Leflunomide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fexofenadine#bnf_i1643857964198",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fexofenadine#bnf_i1643857964198_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"letermovir\" outputclass=\"int-drug\">Letermovir</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"fexofenadine\" outputclass=\"int-heading-drug\">fexofenadine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Letermovir   is predicted to   increase   the concentration of   fexofenadine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "17",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Letermovir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fexofenadine#bnf_i1643857964199",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fexofenadine#bnf_i1643857964199_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"lorlatinib\" outputclass=\"int-drug\">Lorlatinib</ph> <ph outputclass=\"int-effect\">decreases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"fexofenadine\" outputclass=\"int-heading-drug\">fexofenadine</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Lorlatinib   decreases   the exposure to   fexofenadine .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "18",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lorlatinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fexofenadine#bnf_i1643857964200",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fexofenadine#bnf_i1643857964200_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Mild\" outputclass=\"int-message\">\n  <ph otherprops=\"mirabegron\" outputclass=\"int-drug\">Mirabegron</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"fexofenadine\" outputclass=\"int-heading-drug\">fexofenadine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Mild",
							"hasOrder": "1",
							"hasTextContent": "Mirabegron   is predicted to   increase   the exposure to   fexofenadine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "19",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Mirabegron</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fexofenadine#bnf_i1643857964201",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fexofenadine#bnf_i1643857964201_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"neratinib\" outputclass=\"int-drug\">Neratinib</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"fexofenadine\" outputclass=\"int-heading-drug\">fexofenadine</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Neratinib   is predicted to   increase   the exposure to   fexofenadine .  Manufacturer advises monitor .    \n\n"
						}
					],
					"hasOrder": "20",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Neratinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fexofenadine#bnf_i1643857964202",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fexofenadine#bnf_i1643857964202_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"olaparib\" outputclass=\"int-drug\">Olaparib</ph> <ph outputclass=\"int-effectQualifier\">might</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"fexofenadine\" outputclass=\"int-heading-drug\">fexofenadine</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Olaparib   might   increase   the exposure to   fexofenadine .  Manufacturer advises monitor .    \n\n"
						}
					],
					"hasOrder": "21",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Olaparib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fexofenadine#bnf_i1643857964203",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fexofenadine#bnf_i1643857964203_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"osimertinib\" outputclass=\"int-drug\">Osimertinib</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"fexofenadine\" outputclass=\"int-heading-drug\">fexofenadine</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Osimertinib   is predicted to   increase   the exposure to   fexofenadine .  Manufacturer advises monitor .    \n\n"
						}
					],
					"hasOrder": "22",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Osimertinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fexofenadine#bnf_i1643857964204",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fexofenadine#bnf_i1643857964204_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"phenelzine\" outputclass=\"int-drug\">Phenelzine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of antimuscarinic adverse effects when given with</ph> <ph otherprops=\"fexofenadine\" outputclass=\"int-heading-drug\">fexofenadine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Phenelzine   is predicted to   increase   the risk of antimuscarinic adverse effects when given with   fexofenadine .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "23",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Phenelzine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fexofenadine#bnf_i1643857964205",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fexofenadine#bnf_i1643857964205_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"pibrentasvir\" outputclass=\"int-drug\">Pibrentasvir</ph> <ph outputclass=\"int-substanceQualifier\">with glecaprevir</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"fexofenadine\" outputclass=\"int-heading-drug\">fexofenadine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Pibrentasvir   with glecaprevir   is predicted to   increase   the exposure to   fexofenadine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "24",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pibrentasvir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fexofenadine#bnf_i1643857964206",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fexofenadine#bnf_i1643857964206_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Mild\" outputclass=\"int-message\">\n  <ph otherprops=\"pitolisant\" outputclass=\"int-drug\">Pitolisant</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"fexofenadine\" outputclass=\"int-heading-drug\">fexofenadine</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Mild",
							"hasOrder": "1",
							"hasTextContent": "Pitolisant   is predicted to   decrease   the exposure to   fexofenadine .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "25",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pitolisant</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fexofenadine#bnf_i1643857964207",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fexofenadine#bnf_i1643857964207_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"rifampicin\" outputclass=\"int-drug\">Rifampicin</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the clearance of</ph> <ph otherprops=\"fexofenadine\" outputclass=\"int-heading-drug\">fexofenadine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Rifampicin   increases   the clearance of   fexofenadine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "26",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Rifampicin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fexofenadine#bnf_i1643857964208",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fexofenadine#bnf_i1643857964208_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"roxadustat\" outputclass=\"int-drug\">Roxadustat</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"fexofenadine\" outputclass=\"int-heading-drug\">fexofenadine</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor adverse effects and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Roxadustat   is predicted to   increase   the exposure to   fexofenadine .  Manufacturer advises monitor adverse effects and adjust dose .    \n\n"
						}
					],
					"hasOrder": "27",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Roxadustat</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fexofenadine#bnf_i1643857964209",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fexofenadine#bnf_i1643857964209_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"sotorasib\" outputclass=\"int-drug\">Sotorasib</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"fexofenadine\" outputclass=\"int-heading-drug\">fexofenadine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid or adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Sotorasib   is predicted to   increase   the exposure to   fexofenadine .  Manufacturer advises avoid or adjust dose .    \n\n"
						}
					],
					"hasOrder": "28",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sotorasib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fexofenadine#bnf_i1643857964210",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fexofenadine#bnf_i1643857964210_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tepotinib\" outputclass=\"int-drug\">Tepotinib</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"fexofenadine\" outputclass=\"int-heading-drug\">fexofenadine</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tepotinib   is predicted to   increase   the concentration of   fexofenadine .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "29",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tepotinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fexofenadine#bnf_i1643857964211",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fexofenadine#bnf_i1643857964211_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"teriflunomide\" outputclass=\"int-drug\">Teriflunomide</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"fexofenadine\" outputclass=\"int-heading-drug\">fexofenadine</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Teriflunomide   is predicted to   increase   the exposure to   fexofenadine .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "30",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Teriflunomide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fexofenadine#bnf_i1643857964212",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fexofenadine#bnf_i1643857964212_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tranylcypromine\" outputclass=\"int-drug\">Tranylcypromine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of antimuscarinic adverse effects when given with</ph> <ph otherprops=\"fexofenadine\" outputclass=\"int-heading-drug\">fexofenadine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tranylcypromine   is predicted to   increase   the risk of antimuscarinic adverse effects when given with   fexofenadine .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "31",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tranylcypromine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fexofenadine#bnf_i1643857964213",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fexofenadine#bnf_i1643857964213_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"tucatinib\" outputclass=\"int-drug\">Tucatinib</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"fexofenadine\" outputclass=\"int-heading-drug\">fexofenadine</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Tucatinib   is predicted to   increase   the exposure to   fexofenadine .  Manufacturer advises use with caution and adjust dose .    \n\n"
						}
					],
					"hasOrder": "32",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tucatinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fexofenadine#bnf_i1643857964214",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fexofenadine#bnf_i1643857964214_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"vandetanib\" outputclass=\"int-drug\">Vandetanib</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"fexofenadine\" outputclass=\"int-heading-drug\">fexofenadine</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Vandetanib   is predicted to   increase   the exposure to   fexofenadine .  Manufacturer advises monitor .    \n\n"
						}
					],
					"hasOrder": "33",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Vandetanib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fexofenadine#bnf_i1643857964215",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fexofenadine#bnf_i1643857964215_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"velpatasvir\" outputclass=\"int-drug\">Velpatasvir</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"fexofenadine\" outputclass=\"int-heading-drug\">fexofenadine</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Velpatasvir   is predicted to   increase   the exposure to   fexofenadine .  Manufacturer advises monitor .    \n\n"
						}
					],
					"hasOrder": "34",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Velpatasvir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fexofenadine#bnf_i1643857964216",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fexofenadine#bnf_i1643857964216_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"vemurafenib\" outputclass=\"int-drug\">Vemurafenib</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"fexofenadine\" outputclass=\"int-heading-drug\">fexofenadine</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Vemurafenib   is predicted to   increase   the exposure to   fexofenadine .  Manufacturer advises use with caution and adjust dose .    \n\n"
						}
					],
					"hasOrder": "35",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Vemurafenib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fexofenadine#bnf_i1643857964217",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fexofenadine#bnf_i1643857964217_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"venetoclax\" outputclass=\"int-drug\">Venetoclax</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"fexofenadine\" outputclass=\"int-heading-drug\">fexofenadine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Venetoclax   is predicted to   increase   the exposure to   fexofenadine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "36",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Venetoclax</title>"
					}
				}
			],
			"hasSearchLabel": " Fexofenadine  | Interactions",
			"hasSearchLink": {
				"@id": "http://bnf.nice.org.uk/interaction/fexofenadine.html"
			},
			"hasTitle": {
				"@type": "rdf:XMLLiteral",
				"@value": "<title> Fexofenadine </title>"
			},
			"rdfs:label": "fexofenadine"
		}
	]
}